Multinational Phase II study of VINORELBINE (Navelbine) + TRASTUZUMAB (Herceptin) as first-line therapy for HER-2 overexpressing Metastatic Breast Cancer (HER-2 + MBC9)
- Kellokumpu-Lehtinen, P. (Contributor)
Activity: Talk or presentation › Conference presentation